AviadoBio Targets Rare Form Of Dementia With Gene Therapy

With Targeted Thalamus Delivery

The UK biotech hopes to address a fast-progressing form of dementia that affects people earlier in life with a supplemental gene therapy delivered directly to the brain’s information centre.  

EPC AviadoBio
Frontotemporal Dementia Causes Cognitive, Speech And Behavioral Decline • Source: Shutterstock

AviadoBio Ltd. is preparing to take its lead gene therapy program to the clinic in a subset of dementia patients who could benefit from the greater precision of intra-thalamic delivery.

The firm was spun out of research conducted by neuroscientist Chris Shaw at King’s College, London. Shaw’s team focuses on...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Emerging Company Profiles

More from Start-Ups & SMEs